Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast.
Lin Y, Hatem J, Wang J, Quinn A, Hicks D, Tang P
Purpose
The purpose of this paper was to compare estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) immunohistochemical (IHC) staining of tissue microarrays (TMA) and whole sections of breast cancer tissue.
Conclusion
The specificity and sensitivity rates of TMA-based ER IHC were 87.0 and 90.4%, respectively when whole sections were used as the reference. For PR and HER2, the specificity and sensitivity rates were 75.9 and 76.1% and 90.6 and 27.3%, respectively. When the number of TMA cores evaluated increased, non-concordance rates between TMA and whole sections decreased. Tumor size had no effects on non-concordance rates between TMA and whole sections.
Studies (1)
Purpose
The purpose of this study was to compare ER, PR, and HER2 IHC staining of TMA with staining seen in whole sections of ductal carcinoma in situ of the breast. Concordance rates between the two types of slides were evaluated with respect to core number on the TMA. The authors defined positive TMA results as staining in at least 1 of 3 cores.
Summary of Findings
The specificity and sensitivity rates of TMA-based ER IHC were 87.0 and 90.4%, respectively when whole sections were used as the reference. For PR and HER2, the specificity and sensitivity rates were 75.9 and 76.1% and 90.6 and 27.3%, respectively. When the number of TMA cores evaluated was increased from 1 to 2 and 3, non-concordance rates (including discordance and non-informative results) between TMA and whole sections decreased from 46.5% to 22.7% and 11.6%, respectively (p<0.001). Tumor size had no effects on non-concordance rates between TMA and whole sections which were 33.3%, 37.1%, and 39.3% for tumor sizes < 1 cM, 1-2 cM, and > 2 cM, respectively.
Biospecimens
TissueBreastPreservation Types
FormalinDiagnoses
NeoplasticCarcinomaPlatforms
ProteinImmunohistochemistryPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Biospecimen Aliquots and Components Aliquot size/volume 1 TMA core1-2 cM tumor size2 TMA cores3 TMA cores< 1 cM tumor size> 2 cM tumor sizeBiospecimen Aliquots and Components Type of slide TMAWhole sectionImmunohistochemistry Specific Targeted peptide/protein ERHER2PR